Technology evaluation: Electroporation therapy, Genetronics Inc

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 2, 2000, Pages 205-210

  Orr, Rosanne M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; MITOMYCIN C;

ANIMAL EXPERIMENT; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG MECHANISM; EDEMA; ELECTROCHEMOTHERAPY; ELECTROPORATION; GENE THERAPY; HEAD AND NECK CARCINOMA; HUMAN; MOUSE; MUSCLE SPASM; NONHUMAN; PHASE 2 CLINICAL TRIAL; PULSE GENERATOR; REVIEW; SKIN TUMOR; TISSUE NECROSIS; TREATMENT INDICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; BLEOMYCIN; DRUG DELIVERY SYSTEMS; ELECTROPORATION; HUMANS; NEOPLASMS;

ANIMALIA;

EID: 0033993930     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. 191155. Genetronics Inc: The opportunity: Why Genetronics is uniquely positioned to serve the drug delivery market. Company Brochure 5 November (1995).
2. 193232. Heller R, Jaroszeski M, Puleo C, Messina C, Glass F, Perrott R, van Voorhis N, Gilbert R, Mir LM, Reinigen D: Phase I-II treatment of melanoma and other subcutaneous malignancies by electrochemotherapy. Proc Am Assoc Cancer Res (1995) 36:Abs 1475.
3. 242408. Genetronics Inc: Genetronics announces preliminary results of collaboration research project. Press release 26 March (1997).
4. 242546. Bergan R, Hakim F, Schwartz GN, Kyle E, Cepada R, Szabo JM, Fowler D, Gress R, Neckers L: Electroporation of synthetic oligodeoxynucleotides: A novel technique for ex vivo bone marrow purging. Blood (1996) 88:731-741.
5. 243024. Genetronics Biomedical: Genetronics develops the MedPulser, its first clinical system designed to treat solid tumor cancers receives additional patent protection. Press release 18 April (1997).
6. 252087. Genetronics Biomedical: Genetronics allowed patent for needle array applicators; key step in commercializing drug delivery systems. Press release 1 July (1997).
7. 259355. Genetronics Inc: Genetronics receives allowance for 3 patents for inventions to effectively deliver drugs and genes. Press release 14 August (1997).
8. 261255. Genetronics Biomedical: Genetronics listed today on the Toronto Stock Exchange. Press release 2 September (1997).
9. 262776. Genetronics Inc: Genetronics receives second SBIR grant from the national Heart, Lung and Blood Institute Cardiovascular Research. Press release 12 September (1997).
10. 270036. Genetronics Biomedical: Genetronics demonstrates highly efficient gene delivery into tumor cells in vivo. Press relaese 20 November (1997).
11. 273388. Genetronics Biomedical: Genetronics to initiate electroporation therapy trials at French Hospitals - pancreatic, liver cancer. Press release 5 January (1998).
12. 281462. Emerging Pharmaceuticals: Biotech tool used as drug- delivery device for anticancer therapy. (1998) 7(3):7.
13. 282807. Genetronics Biomedical: Genetronics announces promising treatment of human prostate cancer in mice. Press release 1 April (1998).
14. 285601. Genetronics Biomedical: Genetronics announces nine sites for phase II clinical trial in US. Press release 28 April (1998).
15. 286677. Dev SB, Nanda GS, An Z, Wang X, Hofmann RM, Hofmann GA: Effective electroporation therapy of human pancreatic tumors implanted In nude mice. Drug Delivery (1997) 4(4):293-299.
16. 290144. Genetronics Biomedical: Genetronics introduces unique drug delivery system for oncology. Press release 24 June (1998).
17. 291138. Genetronics Biomedical: Genetronics announces successful device trial with unique transdermal drug delivery system to treat erectile dysfunction. Press release 7 July (1998).
18. 297039. Genetronics Biomedical: Electroporation enhances therapeutic efficacy of anticancer drugs to treat pancreatic cancer In mice - Genetronics study published in Anticancer Research journal. Press release 3 September (1998).
19. 302119. Genetronics Biomedical: Genetronics moves ahead to treat prostate cancer; announces preclinical trials testing its unique tumor-killing drug delivery system. Press release 21 October (1998).
20. Bioworld Week: Genetronics, J&J enter licensing, supply deal worth $131M. (1998) 6(41):4.
21. Genetronics Biomedical: http://www.genetronics.com.
22. Genetronics Biomedical: Genetronics announces results of effective delivery of heparin into animal arterial walls published in catheterization and cardiovascular diagnosis journal. Press release 1 December (1998).
23. Goldfarb P, Biel M, Hanna E, Houck J, Klotch D, Nathan C, Panje W, Robbins T, Shaw G, El Sayed S, Hier M, Jones V, Nasser J, Rice D: A phase II study using electroporation and intratumoral bleomycin In patients with recurrent head and neck cancer: A safe and active treatment approach. Proc Am Soc Clin Am (1999) 18:Abs1535.
24. Hofmann GA, Dev SB, Dimmer S, Nanda GS: Electroporation therapy: A new approach for the treatment of head and neck cancer. IEEE TransBiomedEng (1999) 46(6):752-759.
25. Nanda GS, Sun FX, Hofmann GA, Hofmann RM, Dev SB: Electroporation enhances therapeutic efficacy of anticancer drugs: Treatment of human pancreatic tumor in animal model. Anticancer Res (1998) 18(3A):1361-1366.
26. Nanda GS, Sun FX, Hofmann GA, Hofmann RM, Dev SB: Electroporation therapy of human larynx tumors HEp-2 implanted in nude mice. Anticancer Res (1998) 18(2A):999-1004.
27. Panje WR, Hier MP, Garman GR, Harrel E, Goldman A, Bloch I: Electroporation therapy of head and neck cancer. Ann Otol Rhino Laryngol (1998) 107:779-785.
28. Mir LM, Glass LF, Sersa G, Teissie J, Domenge C, Miklavcic D, Jaroszeski MJ, Orlowski S, Reintgen DS, Rudolf Z, Belehradek M, Gilbert R, Rois M-P, Belehradek JJ, Bachaud JM, DeConti R, Stabuc B, Cemazar B, Coninx P, Heller R: Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. Br J Cancer (1998) 77:2336-2342.
29. Sersa G, Cemazar M, Miklavcic D: Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res. (1995) 55:3450-3455.
30. Jaroszeski MJ, Illingworth P, Pottinger C, Hyacinthe M, Heller R: Electrically mediated drug delivery for treating subcutaneous and orthotopic pancreatic adenocarcinoma in a hamster model. Anticancer Res (1999) 19:989-994.
31. Hyacinthe M, Jaroszeski MJ, Dang W, Coppola D, Karl RC, Gilbert RA, Heller R: Electrically enhanced drug delivery for the treatment of soft tissue sarcoma. Cancer (1999) 85:409-417.
32. Heller R, Jaroszeski MJ, Glass LF, Messina JL, Rapaport DP, DeConti RC, Fenske NA, Gilbert RA, Mir LM, Reintgen DS: Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer (1996) 77:964-971.
33. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, Glass LF: Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer (1998) 83:148-157.
34. Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z: Electrochemotherapy with cisplatin: Potentiation of local cisplatin antitumor effectiveness by application of electric pulses in cancer patients. Eur J Cancer (1998) 34:1213-1218.
35. Carriaga MT, Henson DE: Liver, gallbladder, extrahepatic bile and pancreas. Cancer (1995) 75:171-190.
36. Genetronics Inc: Genetronics announces clinical and commercialization plan and management appointment Press release 19 January (2000).
37. Neumann E, Sowers AE, Jordan CA (Eds): Electroporation and Electrofusion in Cell Biology. Plenum Press NY (1989).
38. Chang DC, Chassy BM, Saunders JA, Sowers AE (Eds): Guide to Electroporation and Electrofusion. Academic Press, San Diego, CA (1992).
39. Mir LM, Belehradek M, Domenge C, Ortowski S, Poddevin B, Belehradek JJ, Schwaab G, Luboinski B, Paoletti C: Electrochemotherapy, a novel antitumor treatment: First clinical trial. CR Acad Sci Paris III (1991) 313:613-618.
40. Wingo PA, Tong T, Bolden S: Cancer Stat (1995) 45:12.
41. References to patent literature 101. GENETRONICS INC (Hofmann GA, Hayakawa Y, Heller R, Jaraszeski MJ): Needle electrodes for mediated delivery of drugs and genes. US-05702359.